According to the information disclosed by the National Medical Products Administration on August 27, 2025, Taiyi's new cosmetic ingredient urolitin A (Filing Number: Guo Zhuang Yuan Bei Zi 20250106) has officially passed the filing review. This product is the company's first approved patented new cosmetic ingredient, marking an important breakthrough for Taiyi in the field of innovative raw materials for cutting-edge cell anti-aging cosmetics.
Biological aging is not a single event but a complex process driven by multiple factors. Its core feature is the gradual loss of physiological integrity, leading to functional impairment and increased susceptibility to diseases. Among them, mitochondrial dysfunction is a key characteristic of aging. Urolithin A (UA), as an emerging active substance closely related to mitochondrial autophagy, has become A highly anticipated "mitochondrial anti-aging" star component due to its unique biological effects. Urolithin A focuses on enhancing the quality control and renewal capabilities of cells, specifically maintaining and renewing them. It not only eliminates damaged mitochondria and activates cell energy metabolism but also demonstrates multiple effects such as collagen reconstruction, anti-inflammation, and anti-photoaging in external clinical applications. It truly transitions from "exogenous repair" to "endogenous regulation". Care for the youthful state of your skin from the "root".
The R&D team of Taiyi, in collaboration with experts from multiple fields, has continuously explored innovative applications and strictly controlled the quality and safety of raw materials. Through high-tech standard development work such as quality analysis, stability testing, toxicological assessment, and efficacy evaluation, they have successfully developed the MitoYouth® urolithin A cosmetic raw material, which has been officially recognized by the National Medical Products Administration.
This raw material can be used as a skin protectant in cosmetics. The approval of the new raw material MitoYouth® Urolithin A is an important achievement of Taiyi's commitment to the "high added value, high-tech content, and high-quality standards" of cosmetic raw materials, and it also lays a solid foundation for the subsequent research and development of new products. In the future, Taiyi will take this successful filing as a starting point, continuously increase its investment in research and development in the field of cutting-edge skin care raw materials, explore more innovative raw materials, and inject new vitality into the development of the industry.
Previously, Taiyi Health and Bangshang jointly launched StanYouth® Urolitin A, which takes oral mitochondrial-grade raw materials as its core and precisely targets the anti-aging and cellular health market. This product optimizes mitochondrial function through scientific proportioning, marking Taiyi Health's strategic upgrade from single product application to the coordinated development of internal nourishment and external application.
It has set a dual benchmark for raw material innovation and efficacy verification in the industry. This time, the approval of the filing of MitoYouth® Urolithin A not only broadens the application scenarios of urolithin A in the field of precision nutrition, but also redefines the quality standards of the health category through a dual-track model of "endogenous activation + external intervention". Taiyi Health, taking emerging raw materials as a fulcrum, promotes the transformation of the traditional herbal health industry towards cell-level care, providing consumers with more technologically advanced solutions.